NCT04897477

Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma

An Open Label, Single Arm, Phase I/II in the Combination of Azacytidine, Bendamustine and Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Chinese PLA General Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is an open label, single arm, phase I/II for patients with r/r Non-Hodgkin's Lymphoma . The purpose is to evaluate the safety and efficacy of the combination with Azacytidine, Bendamustine and Piamprizumab

Conditions

• Non-hodgkin Lymphoma,B Cell

Interventions

Type	Name	Description
DRUG	Azacytidine, Bendamustine and Piamprizumab	Azacytidine by means of subcutaneous injection, Bendamustine and Piamprizumab intravenous infusion

Timeline

• Start date: 2021-04-22
• Primary completion: 2022-04-23
• Completion: 2023-04-23
• First posted: 2021-05-21
• Last updated: 2021-05-21

Locations

2 sites across 1 country: China